The CEPHEUS trial is a trial for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplantation, or in whom a transplant was deferred. And 395 patients were randomized ...

TORONTO -- Achieving minimal residual disease (MRD) negativity was associated with favorable safety outcomes and no effect on health-related quality of life among patients with newly diagnosed ...

The first and only test authorized by the FDA to detect and monitor minimal residual disease (MRD) in multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL) has received coverage for ...

(RTTNews) - The Landmark CIRCULATE-Japan Study Showed Natera Inc.'s (NTRA) Signatera MRD Test is predictive of chemotherapy benefit in Colorectal Cancer. More than 3,000 cohort of colorectal cancer or ...

Flatiron Health and Exact Sciences collaborate to use Flatiron's platform for rapid data analysis with the Oncodetect MRD test. The study involves 1350 patients in community settings, focusing on ...

This collection describes the impact of pre-transplant molecular measurable residual disease (MRD) on acute myeloid leukemia (AML) prognosis. The original pre-MEASURE study demonstrated the superior ...

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus ...